BRIEF published on 10/15/2024 at 07:35, 5 months 23 days ago MaaT Pharma Clinical Trial Recruitment Concluded Clinical Trial MaaT Pharma MaaT013 DSMB Notice AGvH Treatment
BRIEF published on 10/15/2024 at 07:35, 5 months 23 days ago Conclusion du recrutement pour l'essai clinique de MaaT Pharma Essai Clinique MaaT Pharma MaaT013 Avis DSMB Traitement AGvH
PRESS RELEASE published on 10/15/2024 at 07:30, 5 months 23 days ago Informations privilégiées / Autres communiqués MaaT Pharma annonce la fin du recrutement de son essai de Phase 3 ARES pour MaaT013 dans le traitement de la maladie aiguë du greffon contre l'hôte. Premiers résultats attendus en janvier 2025 MaaT Pharma MaaT013 Phase 3 ARES Maladie Aiguë Greffon Contre L'hôte
PRESS RELEASE published on 10/15/2024 at 07:30, 5 months 23 days ago Inside Information / Other news releases MaaT Pharma completes recruitment of its ARES Phase 3 Trial for MaaT013, a treatment for Acute Graft-versus-Host Disease, with topline results expected in January 2025 Clinical Trial MaaT Pharma MaaT013 ARES Phase 3 Trial Acute Graft-versus-Host Disease
PRESS RELEASE published on 09/20/2024 at 09:07, 6 months 17 days ago Rapport Financier Semestriel 2024
BRIEF published on 09/04/2024 at 07:35, 7 months 3 days ago MaaT Pharma Announces Participation in Investor and Medical Conferences in September Investors Cancers Medical Conference MET Therapies Cell Transplantation
BRIEF published on 09/04/2024 at 07:35, 7 months 3 days ago MaaT Pharma annonce sa participation à des conférences investisseurs et médicales en septembre Investisseurs Conférence Médicale Thérapies MET Transplantation Cellulaire Cancers
PRESS RELEASE published on 09/04/2024 at 07:30, 7 months 3 days ago Informations privilégiées / Autres communiqués MaaT Pharma annonce sa participation aux conférences investisseurs et médicales en septembre, avec des présentations lors du Congrès annuel de la Society of Hematologic Oncology à Houston et à d'autres événements internationaux Conférences Investisseurs Microbiote MaaT Pharma Cancers
BRIEF published on 05/15/2024 at 07:35, 10 months 23 days ago MaaT Pharma successfully completes a fundraising of 19.2 million euros Biotechnology Fundraising Investment MaaT Pharma Clinical Tests
BRIEF published on 05/15/2024 at 07:35, 10 months 23 days ago MaaT Pharma clôture avec succès une levée de fonds de 19,2 millions d'euros Investissement Biotechnologie Essais Cliniques Levée De Fonds MaaT Pharma
Published on 04/07/2025 at 14:30, 27 minutes ago Newsmax Enters into Standby Equity Purchase Agreement of Up to $1.2 Billion With Yorkville Advisors
Published on 04/07/2025 at 14:30, 27 minutes ago Sparta Provides Update on Delay in Filing Annual Financial Statements
Published on 04/07/2025 at 14:00, 57 minutes ago NOA Lithium Advances Towards 2025 Water Exploration at Rio Grande Project
Published on 04/07/2025 at 14:00, 57 minutes ago Rio Grande Resources Announces the Successful Completion of Sampling and Field Campaign at the Winston Gold-Silver Project
Published on 04/07/2025 at 14:00, 57 minutes ago Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology
Published on 04/07/2025 at 14:24, 32 minutes ago OTRS AG: Voluntary Public Tender Offer of Optimus BidCo AG
Published on 04/07/2025 at 13:00, 1 hour 57 minutes ago CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Published on 04/07/2025 at 12:57, 2 hours ago PFISTERER acquires long-standing partner Power CSL - portfolio expanded to include subsea solutions
Published on 04/07/2025 at 11:57, 2 hours 59 minutes ago Share buyback: Announcement pursuant to Article 5 (1) (b) and (3) of Regulation (EU) No. 596/2014
Published on 04/07/2025 at 07:01, 7 hours 56 minutes ago bioMérieux obtient le marquage CE pour LUMED™ APSS™, une solution logicielle de pointe pour aider à prendre des décisions en matière de bon usage des antibiotiques
Published on 04/07/2025 at 07:01, 7 hours 56 minutes ago bioMérieux obtains CE-marking for LUMED™ APSS™, a cutting-edge software solution to aid medical decision-making in Antimicrobial Stewardship
Published on 04/04/2025 at 19:18, 2 days 19 hours ago Mersen: Number of shares and voting rights as of March 31, 2025
Published on 04/04/2025 at 19:18, 2 days 19 hours ago Mersen : nombre d'actions et de droits de vote au 31 mars 2025
Published on 04/04/2025 at 18:17, 2 days 20 hours ago Reporting on share buyback transactions carried out between March 31 and April 3, 2025
